Ignite Creation Date:
2025-12-24 @ 5:42 PM
Ignite Modification Date:
2025-12-25 @ 3:11 PM
Study NCT ID:
NCT05268068
Status:
COMPLETED
Last Update Posted:
2022-03-07
First Post:
2022-03-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-27
Start Date Type:
ACTUAL
Primary Completion Date:
2020-04-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-04-26
Completion Date Type:
ACTUAL
First Submit Date:
2022-03-03
First Submit QC Date:
None
Study First Post Date:
2022-03-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-03
Last Update Post Date:
2022-03-07
Last Update Post Date Type:
ACTUAL